1 of 998 DOCUMENTS
US Fed News
January 25, 2012 Wednesday 2:06 PM EST
GRANT WILL FUND STUDY OF COGNITION AND SCHIZOPHRENIA
LENGTH: 927 words
SACRAMENTO, Calif., Jan. 25 -- The University of California issued
the following
press release:
Michael Minzenberg, a UC Davis psychiatry researcher, has been
awarded a
prestigious three-year, $200,000 seed grant from the Dana Foundation
to study
the brains of patients being treated for schizophrenia to determine
how
additional treatment to improve cognition interacts with antipsychotic
medication.
"Cognition is very important in schizophrenia because it is a strong
predictor
of outcome. It determines whether a person can be a contributing
member of a
community, stay out of the hospital and live independently," said
Minzenberg,
associate professor in the Department of Psychiatry and Behavioral
Sciences and
a faculty member of the UC Davis Imaging Research Center.
Schizophrenia is a chronic mental disorder characterized by decline
in thought
processes and loss of emotional responsiveness. It affects 3.2 million
Americans, the majority of whom are not receiving treatment. It can
lead to
auditory hallucinations, paranoia and delusions.
Despite the importance of cognition in the rehabilitation of those
with
schizophrenia, there are no U.S. Food and Drug Administration
(FDA)-approved
drugs for the improvement of cognition in this patient population.
"Dr. Minzenberg is at the forefront of trying to develop therapies
for impaired
cognition in schizophrenia, using powerful new non-invasive brain
imaging to
measure the effects of drugs and other treatments on functional
networks in the
brain," said Cameron Carter, director of the Center for Neuroscience
and the
Imaging Research Center at UC Davis.
"His work is suggesting that some of the other medications that
patients are
taking may interfere with the procognitive effects of some of the
newer more
promising therapies. If this proves to be true then it will be
important to
'fine tune' patients' medications to optimize cognitive outcomes in
people with
schizophrenia and other brain disorders."
Modafinil is a drug approved by the FDA for the treatment of
narcolepsy. It is
also known by the brand name Provigil. Narcolepsy is a chronic
neurological
disease characterized by sudden urges to sleep, episodes of loss of
voluntary
muscle tone, vivid dreams while falling asleep or upon awakening, and
brief
episodes of total paralysis while waking up from sleep. Both genetic
and
environmental factors appear to contribute to narcolepsy. Although no
cure
exists, medications can often help restore a patient's quality of
life.
Like other stimulants, Modafinil's side effects are relatively mild.
It is used
off-label to combat the effects of sedatives. Currently, it is not
prescribed on
a long-term basis to schizophrenia patients.
However, Minzenberg and his colleagues conducted a small, unpublished
pilot
study that showed Modafinil can improve cognition in patients being
treated for
schizophrenia.
"What we understand about how Modafinil works in the brain leads us
to believe
that it might be good for improving cognition deficits of our
patients,"
Minzenberg said.
Because the cause of schizophrenia is unknown, treatment focuses on
eliminating
symptoms. Antipsychotic drugs are effective at reducing its most
serious
symptoms: delusions and hallucinations. Any treatment to improve
cognition
cannot interact with these drugs in a negative way.
"The use of antipsychotic medications is the standard of care in
patients with
schizophrenia. So, before we can move forward with a large clinical
trial
involving Modafinil's impact on cognition, we need to know how it
interacts with
these drugs."
Cognition refers to a range of high-level brain functions, including
the
abilities to learn, remember information, organize, plan,
problem-solve and
understand and use language. It is thought to be controlled by an
area of the
brain called the locus coeruleus, which controls the body's
physiological
responses to stress and panic, commonly referred to as the "fight or
flight"
response.
"This area of the brain also serves to coordinate activity in the
entire brain
as it performs almost any type of task or behavior," Minzenberg said.
Minzenberg and his colleagues will conduct the study at the UC Davis
Early
Diagnosis and Preventive Treatment of Psychosis (EDAPT) Clinic.
Researchers will
enroll 60 patients newly diagnosed with schizophrenia. These patients
will have
a specialized brain scan performed, called functional magnetic
resonance imaging
or fMRI, and will be randomly assigned to an FDA-approved treatment
for
schizophrenia.
After eight weeks of treatment, another fMRI scan will be conducted.
The
patients, who also will have been assigned to either a control or
study group,
will undergo a third scan while performing a cognitive task.
Functional magnetic resonance imaging allows researchers to see
changes in blood
flow related to neural activity. Minzenberg and his colleagues will
examine
whether patients being treated with Modafinil perform better or
worse, as
measured by the changes in activity in locus coeruleus, depending on
which
antipsychotic medication they receive.
"We are hoping to find evidence that using Modafinil we can improve
brain
function in stable schizophrenia patients," Minzenberg said.
The New York-based Dana Foundation is a private philanthropic
organization that
supports clinical research in neuroscience and neuroimmunology and
their
interrelationship in human health and disease. For further
information, visit
www.dana.org. For any query with respect to this article or any other
content
requirement, please contact Editor at htsyndication@hindustantimes.com
LOAD-DATE: January 26, 2012
LANGUAGE: ENGLISH
PUBLICATION-TYPE: Newswire
Copyright 2012 HT Media Ltd.
All Rights Reserved
2 of 998 DOCUMENTS
CNS Drug News
November 29, 2011
Modiodal approved for additional indication in Japan
SECTION: NEWS
LENGTH: 154 words
Alfresa Pharma (Alfresa Holdings) has received approval in Japan of a
partial
change in the indications of Modiodal (modafinil) Tablets 100mg, a
sleep
disorder treatment that has been jointly developed in the country with
Mitsubishi Tanabe Pharma.
Since March 2007, Modiodal has been jointly marketed by the companies
as a
treatment for excessive daytime sleepiness associated with
narcolepsy. The new
indication, approved for the first time in Japan, is "excessive
diurnal
sleepiness accompanied with obstructive sleep apnoea syndrome under
treatment
for airway obstruction by continuous positive airway pressure therapy
and the
like".
Modafinil is a wakefulness-enhancing agent to which Alfresa acquired
the right
to develop, manufacture and market in Japan from Cephalon in June
1998. The drug
is currently approved in more than 30 countries, and in seven,
including the US,
it is marketed with approval for the new indication.
LOAD-DATE: November 29, 2011
LANGUAGE: ENGLISH
PUBLICATION-TYPE: Newsletter
JOURNAL-CODE: CNS Drug News
Copyright 2011 Espicom Business Intelligence
All Rights Reserved
3 of 998 DOCUMENTS
CNS Drug News
November 29, 2011
Modiodal approved for additional indication in Japan
SECTION: NEWS
LENGTH: 154 words
Alfresa Pharma (Alfresa Holdings) has received approval in Japan of a
partial
change in the indications of Modiodal (modafinil) Tablets 100mg, a
sleep
disorder treatment that has been jointly developed in the country with
Mitsubishi Tanabe Pharma.
Since March 2007, Modiodal has been jointly marketed by the companies
as a
treatment for excessive daytime sleepiness associated with
narcolepsy. The new
indication, approved for the first time in Japan, is "excessive
diurnal
sleepiness accompanied with obstructive sleep apnoea syndrome under
treatment
for airway obstruction by continuous positive airway pressure therapy
and the
like".
Modafinil is a wakefulness-enhancing agent to which Alfresa acquired
the right
to develop, manufacture and market in Japan from Cephalon in June
1998. The drug
is currently approved in more than 30 countries, and in seven,
including the US,
it is marketed with approval for the new indication.
LOAD-DATE: January 6, 2012
LANGUAGE: ENGLISH
PUBLICATION-TYPE: Newsletter
JOURNAL-CODE: CNS Drug News
Copyright 2011 Espicom Business Intelligence
All Rights Reserved
4 of 998 DOCUMENTS
The Pharmaceutical Journal
November 29, 2011 Tuesday
Modafinil indication and dosage error in BNF 62
LENGTH: 80 words
HIGHLIGHT: An error is included under the indications and dosage
information for
modafinil that are printed in the British National Formulary 62...
An error is included under the indications and dosage information for
modafinil
that are printed in the British National Formulary 62 (section 4.4,
pp250-251).
Modafinil is listed as indicated for the treatment of daytime
sleepiness
associated with narcolepsy, obstructive sleep apnoea syndrome and
chronic shift
work sleep disorder. The entry should list daytime sleepiness
associated with
narcolepsy only.
Corrected indication and dosage information is available on the BNF
website.
LOAD-DATE: November 29, 2011 Tuesday
LANGUAGE: ENGLISH
PUBLICATION-TYPE: Journal
Copyright 2011 PJ Online
All Rights Reserved
5 of 998 DOCUMENTS
IPR
November 25, 2011 Friday 3:11 PM EST
India Tender Notice: South Central Railway Seeks "Modafinil 100 Mg
Tablets"
LENGTH: 87 words
DATELINE: SECUNDERABAD, Andhra Pradesh
SECUNDERABAD, Andhra Pradesh, Dec. 5 -- South Central Railway has a
requirement
for "Modafinil 100 Mg Tablets."
Tender Bidding Type: Domestic Competitive Bidding
According to the description: "Tenders are invited for Supply of
Modafinil 100
Mg Tab - 7500 Nos"
The tender ref. no. is L-883/2011-2012.
Project Location: India
The expression of interest should be received by Dec. 5 till 1:00
p.m. For any
query with respect to this article or any other content requirement,
please
contact Editor at htsyndication@hindustantimes.com
LOAD-DATE: November 25, 2011
LANGUAGE: ENGLISH
PUBLICATION-TYPE: Newspaper
Copyright 2011 HT Media Ltd.
All Rights Reserved
6 of 998 DOCUMENTS
Targeted News Service
November 7, 2011 Monday 10:51 PM EST
Teva Pharmaceutical Industries Assigned Patent
BYLINE: Targeted News Service
LENGTH: 238 words
DATELINE: Alexandria, Va.
ALEXANDRIA, Va., Nov. 7 -- Teva Pharmaceutical Industries, Petah
Tiqva, Israel,
has been assigned a patent (8,048,222) developed by Arina Ceausu,
Rishon Lezion,
Israel, Anita Lieberman, Ramat Aviv, Israel, and Judith Aronhime,
Rechovot,
Israel, for a highly pure modafinil.
The abstract of the patent published by the U.S. Patent and Trademark
Office
states: "The present invention provides an improved process for
preparing
modafinil, whereby it may be isolated in high purity by a single
crystallization. The process produces modafinil free of sulphone
products of
over-oxidation and other byproducts. The invention further provides
new
crystalline Forms II-VI of modafinil and processes for preparing
them. Each of
the new forms is differentiated by a unique powder X-ray diffraction
pattern.
The invention further provides pharmaceutical compositions containing
novel
modafinil Forms II-IV and VI."
The patent application was filed on Sept. 23, 2004 (10/947,228). The
full-text
of the patent can be found at
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&
u=%2Fnetah
tml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,048,222&
OS=8,048,2
22&RS=8,048,222
Written by Satyaban Rath; edited by Hemanta Panigrahi.
For more information about Targeted News Service federal patent
awards please
contact: Myron Struck, Editor, Direct: 703/866-4708, Cell:
703/304-1897,
Myron@targetednews.com
SR1107HP1107-666772
LOAD-DATE: November 7, 2011
LANGUAGE: ENGLISH
PUBLICATION-TYPE: Newswire
Copyright 2011 Targeted News Service LLC
All Rights Reserved
7 of 998 DOCUMENTS
Health Daily Digest
November 4, 2011 Friday
Modafinil may not affect Operating Skills of Weary Surgeons
LENGTH: 164 words
DATELINE: U.S.
U.S., Nov. 4 -- Weary surgeons may benefit with the intake of
sleep-fighting
medication modafinil by having an enhanced brain power but it may not
bring any
changes in their operating skills, according to a new study.
The research was carried out on 39 young surgeons. They were made to
be awake
throughout the night. As many as 50 percent of doctors were given a
modafinil
pill and the remaining were provided with a dummy pill. The doctors
went through
some psychological tests and did a virtual surgery on a simulator as
early as 6
a.m in the morning.
It was observed that having a sleep-fighting medication modafinil
improved the
brain power of weary surgeons but it was of no use as far as
enhancing their
operating skills in a simulator is concerned.
Written by Manishika Miglani Published by HT Syndication with
permission from
Health Daily Digest. For any query with respect to this article or
any other
content requirement, please contact Editor at
htsyndication@hindustantimes.com
LOAD-DATE: November 15, 2011
LANGUAGE: ENGLISH
PUBLICATION-TYPE: Newspaper
Copyright 2011 HT Media Ltd.
All Rights Reserved
8 of 998 DOCUMENTS
Indian Patents News
October 22, 2011 Saturday 6:30 AM EST
Cephalon Inc Receives Patent for a Pharmaceutical Composition
LENGTH: 262 words
New Delhi, Oct. 22 -- Cephalon Inc received patent for a
pharmaceutical
composition on April 11, 2008. The patent number issued by the Indian
Patent
Office is 218719.
Cephalon Inc had filed patent application number IN/PCT/2002/128/KOL
for a
pharmaceutical composition on Jan. 25, 2002. The inventors of the
patent are
Miller Matthew S and Scammell Thomas E.
The International classification number is A61K31/165.
The PCT International application number of the patent is
PCT/US00/22338 and the
application was filed on Aug. 16, 2000.
According to the Controller General of Patents, Designs & Trade
Marks, "
Modafinil is effective in improving symptoms of attention deficit
hyperactivity
disorder and symptoms of multiple sclerosis fatigue. The
administration of
modafinil is also shown to activate the tuberomamillary neurons of
the posterior
hypothalamus, and thus exhibits activity in an area of the brain
associated with
normal wakefulness functions. A method of identifying a compound that
selectively modulates activity of the tuberomamillary nucleus of the
posterior
hypothalamus is also disclosed."
About the Company
Cephalon, Inc. (NASDAQ: CEPH) is a U.S. biopharmaceutical company
co-founded in
1987 by Dr. Frank Baldino, Jr., a pharmacologist and former scientist
with the
DuPont Company, who served as the company's chairman and chief
executive officer
until his death in December 2010.[2] The company's name comes from
the adjective
"cephalic" meaning "related to the head or brain," and it was
established
primarily to pursue treatments for neurodegenerative diseases.
LOAD-DATE: October 22, 2011
LANGUAGE: ENGLISH
PUBLICATION-TYPE: Newswire
Copyright 2011 Indian Patents News, distributed by
Contify.com
All Rights Reserved
9 of 998 DOCUMENTS
World Generic Market
October 21, 2011
Teva completes Cephalon acquisition
SECTION: NEWS
LENGTH: 967 words
Teva Pharmaceutical Industries announced on 14th October 2011 that it
had
completed its acquisition of Cephalon. The firm had initially
announced it had
acquired all of Cephalon's outstanding shares for US $81.50 per share
in cash in
May 2011; the deal amounted to a total enterprise value of some US
$6.8 billion.
With the acquisition of Cephalon now completed, Teva commented that
the combined
company would have a significant presence in over 60 countries and
generated
around US $20 billion in revenues on a pro-forma basis for the year
ended June
2011.
The completion of the deal came after two hurdles were cleared. On
7th October
2011, Teva reported that the US Federal Trade Commission had accepted
a proposed
consent order in connection with the transaction and granted early
termination
of the Hart-Scott-Rodino waiting period. The FTC had complained that
the
acquisition as originally proposed would have violated US antitrust
law by
reducing competition in three markets: transmucosal fentanyl citrate
lozenges
used to treat cancer pain; extended-release cyclobenzaprine
hydrochloride used
as a muscle relaxant; and modafinil tablets used to improve
wakefulness.
The FTC commented that transmucosal fentanyl citrate lozenges are
versions of a
cancer pain drug developed by Cephalon and marketed under the brand
name Actiq.
Three generic versions of the drug, manufactured and marketed by
Teva, Cephalon
/ Watson Pharmaceuticals and Covidien, currently exist in the US.
Teva's
acquisition of Cephalon would have reduced this to two, and would
have given
Teva a more than 80% share of the sales of generic Actiq.
Extended-release
cyclobenzaprine hydrochloride is the generic form of Amrix. The FTC
noted that
Cephalon had acquired the rights to the branded version, which was
approved by
the FDA in 2007. Currently, no generic versions of the drug are
marketed in the
US, but the FTC argued that Teva and Cephalon were two of only a
limited number
of suppliers that could enter the market quickly with a generic
version. As a
result, combining the two firms would reduce competition in the
future.
Modafinil tablets are generic versions of the brand drug Provigil,
marketed by
Cephalon and used to treat excessive sleepiness caused by narcolepsy
or shift
work disorder. The FTC noted again that no companies currently
market a generic
version of the product, which had sales worth US $1 billion in 2010.
Teva,
Ranbaxy Pharmaceuticals, Mylan Pharmaceutical and Barr Laboratories
(another
Teva company) have all taken steps to enter the market, and are all
eligible to
seek the 180-days marketing exclusivity allowed under the
Hatch-Waxman Act for
being the first to file an ANDA. However, the FTC noted that each
company had
also signed an agreement with Cephalon to refrain from marketing a
generic
version until April 2012. The FTC contended that without the proposed
settlement, Teva and Cephalon would have been two of only a limited
number of
suppliers of generic Provigil during the 180-day period.
In order to replace the competition potentially lost through the
acquisition,
the FTC proposed a settlement order which would require Teva to sell
all of its
rights and assets related to generic Actiq or transmucosal fentanyl
citrate
lozenges, Actiq or generic extended-release cyclobenzaprine
hydrochloride
capsules, to Par Pharmaceutical Companies. With regard to modafinil,
the FTC's
proposed order required Teva to enter into a supply agreement to
provide Par
with generic modafinil tablets in the US for one year. This would
allow Par to
compete with a generic modafinil product during the 180-day
exclusivity period.
In addition, Par may extend the agreement for another year.
Across the Atlantic
The second hurdle to the transaction had been in Europe. In April
2011, before
Teva had announced its acquisition agreement, the European Commission
reported
that it had opened a formal antitrust investigation regarding an
agreement
between Teva and Cephalon that was unconnected with the acquisition.
The EC had
reported that in December 2005, the two firms had settled patent
infringement
disputes in the US and UK concerning modafinil, with Teva undertaking
as part of
the agreement not to sell its generic version in the European
Economic Area
markets before October 2012. The EC was investigating whether this
agreement
may have had the object or effect of hindering generic competition
for the drug
in the EEA.
On 14th October 2011, the EC formally announced that it had cleared
the proposed
acquisition of Cephalon under the EU Merger Regulation. However, the
decision
was conditional upon the divestment of Cephalon's generic version of
its
Provigil product. The Commission commented that it had examined the
effects of
the proposed transaction on the market for modafinil drugs, having
had concerns
that the acquisition, as originally proposed, would have
significantly reduced
generic competition. The Commission determined that the divestment of
Cephalon's generic pipeline modafinil product, as was offered by the
company,
would allow a competitor to emerge and compete effectively with the
Teva /
Cephalon combined company. The investigation did not reveal any other
significant modification to the competitive situation and dynamics of
other
relevant markets, as a number of significant and credible competitors
would
continue to exercise a competitive constraint on the merged entity.
Consequently, the Commission was happy with the modified transaction
proposal.
Teva noted that it was required to divest Cephalon's marketing
authorisation of
generic modafinil in France and grant to the purchaser of the
marketing
authorisation certain additional rights with respect to the entire
EEA,
including a covenant not to sue effective as of October 2012.
LOAD-DATE: October 21, 2011
LANGUAGE: ENGLISH
PUBLICATION-TYPE: Newsletter
JOURNAL-CODE: World Generic Markets
Copyright 2011 Espicom Business Intelligence
All Rights Reserved
10 of 998 DOCUMENTS
World Generic Market
October 21, 2011
Teva completes Cephalon acquisition
SECTION: NEWS
LENGTH: 967 words
Teva Pharmaceutical Industries announced on 14th October 2011 that it
had
completed its acquisition of Cephalon. The firm had initially
announced it had
acquired all of Cephalon's outstanding shares for US $81.50 per share
in cash in
May 2011; the deal amounted to a total enterprise value of some US
$6.8 billion.
With the acquisition of Cephalon now completed, Teva commented that
the combined
company would have a significant presence in over 60 countries and
generated
around US $20 billion in revenues on a pro-forma basis for the year
ended June
2011.
The completion of the deal came after two hurdles were cleared. On
7th October
2011, Teva reported that the US Federal Trade Commission had accepted
a proposed
consent order in connection with the transaction and granted early
termination
of the Hart-Scott-Rodino waiting period. The FTC had complained that
the
acquisition as originally proposed would have violated US antitrust
law by
reducing competition in three markets: transmucosal fentanyl citrate
lozenges
used to treat cancer pain; extended-release cyclobenzaprine
hydrochloride used
as a muscle relaxant; and modafinil tablets used to improve
wakefulness.
The FTC commented that transmucosal fentanyl citrate lozenges are
versions of a
cancer pain drug developed by Cephalon and marketed under the brand
name Actiq.
Three generic versions of the drug, manufactured and marketed by
Teva, Cephalon
/ Watson Pharmaceuticals and Covidien, currently exist in the US.
Teva's
acquisition of Cephalon would have reduced this to two, and would
have given
Teva a more than 80% share of the sales of generic Actiq.
Extended-release
cyclobenzaprine hydrochloride is the generic form of Amrix. The FTC
noted that
Cephalon had acquired the rights to the branded version, which was
approved by
the FDA in 2007. Currently, no generic versions of the drug are
marketed in the
US, but the FTC argued that Teva and Cephalon were two of only a
limited number
of suppliers that could enter the market quickly with a generic
version. As a
result, combining the two firms would reduce competition in the
future.
Modafinil tablets are generic versions of the brand drug Provigil,
marketed by
Cephalon and used to treat excessive sleepiness caused by narcolepsy
or shift
work disorder. The FTC noted again that no companies currently
market a generic
version of the product, which had sales worth US $1 billion in 2010.
Teva,
Ranbaxy Pharmaceuticals, Mylan Pharmaceutical and Barr Laboratories
(another
Teva company) have all taken steps to enter the market, and are all
eligible to
seek the 180-days marketing exclusivity allowed under the
Hatch-Waxman Act for
being the first to file an ANDA. However, the FTC noted that each
company had
also signed an agreement with Cephalon to refrain from marketing a
generic
version until April 2012. The FTC contended that without the proposed
settlement, Teva and Cephalon would have been two of only a limited
number of
suppliers of generic Provigil during the 180-day period.
In order to replace the competition potentially lost through the
acquisition,
the FTC proposed a settlement order which would require Teva to sell
all of its
rights and assets related to generic Actiq or transmucosal fentanyl
citrate
lozenges, Actiq or generic extended-release cyclobenzaprine
hydrochloride
capsules, to Par Pharmaceutical Companies. With regard to modafinil,
the FTC's
proposed order required Teva to enter into a supply agreement to
provide Par
with generic modafinil tablets in the US for one year. This would
allow Par to
compete with a generic modafinil product during the 180-day
exclusivity period.
In addition, Par may extend the agreement for another year.
Across the Atlantic
The second hurdle to the transaction had been in Europe. In April
2011, before
Teva had announced its acquisition agreement, the European Commission
reported
that it had opened a formal antitrust investigation regarding an
agreement
between Teva and Cephalon that was unconnected with the acquisition.
The EC had
reported that in December 2005, the two firms had settled patent
infringement
disputes in the US and UK concerning modafinil, with Teva undertaking
as part of
the agreement not to sell its generic version in the European
Economic Area
markets before October 2012. The EC was investigating whether this
agreement
may have had the object or effect of hindering generic competition
for the drug
in the EEA.
On 14th October 2011, the EC formally announced that it had cleared
the proposed
acquisition of Cephalon under the EU Merger Regulation. However, the
decision
was conditional upon the divestment of Cephalon's generic version of
its
Provigil product. The Commission commented that it had examined the
effects of
the proposed transaction on the market for modafinil drugs, having
had concerns
that the acquisition, as originally proposed, would have
significantly reduced
generic competition. The Commission determined that the divestment of
Cephalon's generic pipeline modafinil product, as was offered by the
company,
would allow a competitor to emerge and compete effectively with the
Teva /
Cephalon combined company. The investigation did not reveal any other
significant modification to the competitive situation and dynamics of
other
relevant markets, as a number of significant and credible competitors
would
continue to exercise a competitive constraint on the merged entity.
Consequently, the Commission was happy with the modified transaction
proposal.
Teva noted that it was required to divest Cephalon's marketing
authorisation of
generic modafinil in France and grant to the purchaser of the
marketing
authorisation certain additional rights with respect to the entire
EEA,
including a covenant not to sue effective as of October 2012.
LOAD-DATE: January 6, 2012
LANGUAGE: ENGLISH
PUBLICATION-TYPE: Newsletter
JOURNAL-CODE: World Generic Markets
Copyright 2011 Espicom Business Intelligence
All Rights Reserved
11 of 998 DOCUMENTS
Global Insight
October 19, 2011
Teva Sells Three Generic Products Rights to Par Pharma
BYLINE: Georgette Calnan
SECTION: In Brief
LENGTH: 242 words
US firm Par Pharmaceutical yesterday (18 October) announced the
ownership of the
rights to three products from Teva (Israel) as a result of the terms
attached by
the US Federal Trade Commission (FTC) to the latter's acquisition of
Cephalon
(US). Under the terms of the agreement, Par will now own the
Abbreviated New
Drug Applications (ANDAs) of the generic versions of Actiq (fentanyl
citrate
lozenges), Amriz (cyclobenzaprine extended-release--ER--capsules), as
well as
the US rights to market the generic version of Provigil (modafinil).
According
to Par's press release, citing IMS data, Actiq, Provigil and Amrix
achieved
annual sales in the US of USD173 million, USD1.1 billion and USD125
million
respectively. Par will begin immediate shipment of all strengths of
fentanyl
citrate lozenges which were previously available from Teva.
Cyclobenzaprine ER
capsules and modafinil tablets are not yet available.
Significance:The deal was part of the US Federal Trade Commission
(FTC)'s
conditional nod of Teva's acquisition of Cephalon. The sale of the
ANDAs allowed
Teva to complete its acquisition of Cephalon by its targeted deadline
of 14
October. Par's acquisition of the three products preserves
competition in all
relevant markets. This will boost the US firm's generic drug
portfolio which in
turn could result in increased revenues. The acquisition of Amrix and
Provigil
ANDAs will allow Par to enter the generic market for both products
next year.
LOAD-DATE: October 19, 2011
LANGUAGE: ENGLISH
PUBLICATION-TYPE: Web Publication
Copyright 2011 World Markets Research Limited
All Rights Reserved
12 of 998 DOCUMENTS
India Investment News
October 18, 2011 Tuesday 6:30 AM EST
Par Pharmaceutical Acquires Three Generic Products from Teva
Pharmaceuticals
LENGTH: 173 words
New Delhi, Oct. 18 -- Par Pharmaceutical Companies Inc. issued the
following
news release:
Par Pharmaceutical Companies, Inc. (NYSE: PRX) announced today that
it acquired
rights to three products from Teva Pharmaceuticals in connection with
Teva's
acquisition of Cephalon. Under terms of the agreement, Par will own
the ANDAs of
fentanyl citrate lozenges, a generic version of Actiq, and
cyclobenzaprine ER
capsules, the generic version of Amrix, as well as the U.S. rights to
market
modafinil tablets, the generic version of Provigil.
According to IMS Health data, annual sales in the U.S. for Actiq and
the
equivalent generic products are $173 million. Annual sales in the
U.S. for
Provigil and Amrix are approximately $1.1 billion and $125 million,
respectively.
Par is currently shipping to the trade all strengths of fentanyl
citrate
lozenges that were previously available from Teva. Cyclobenzaprine ER
capsules
and modafinil tablets were not previously marketed by Teva and are
not yet
available.
Source: Par Pharmaceutical Companies Inc.
LOAD-DATE: January 3, 2012
LANGUAGE: ENGLISH
PUBLICATION-TYPE: Web Publication
Copyright 2011 Contify.com
All Rights Reserved
13 of 998 DOCUMENTS
Key Pharma News
October 18, 2011 Tuesday
Par acquires three generic products from Teva
SECTION: NEWS
LENGTH: 177 words
Par Pharmaceutical Companies has acquired rights to three products
from Teva
Pharmaceutical Industries in connection with the latter's acquisition
of
Cephalon.
Under terms of the agreement, Par will own the ANDAs for fentanyl
citrate
lozenges, a generic version of Actiq, which is indicated for the
management of
breakthrough cancer pain in patients aged >=16 years with
malignancies who are
already receiving and tolerant to around-the-clock opioid therapy for
their
underlying persistent cancer pain, and cyclobenzaprine
extended-release (ER)
capsules, a generic version of Amrix, indicated as an adjunct to rest
and
physical therapy for the relief of muscle spasm associated with
acute, painful
musculoskeletal conditions, as well as the US rights to market
modafinil
tablets, a generic version of Provigil, a wakefulness-promoting agent.
Par is currently shipping all strengths of fentanyl citrate lozenges
that were
previously available from Teva. Cyclobenzaprine ER capsules and
modafinil
tablets were not previously marketed by Teva, and are not yet
available.
LOAD-DATE: October 18, 2011
LANGUAGE: ENGLISH
PUBLICATION-TYPE: Newsletter
JOURNAL-CODE: Pharma Company Insight
Copyright 2011 Espicom Business Intelligence
All Rights Reserved
14 of 998 DOCUMENTS
Key Pharma News
October 18, 2011 Tuesday
Par acquires three generic products from Teva
SECTION: NEWS
LENGTH: 177 words
Par Pharmaceutical Companies has acquired rights to three products
from Teva
Pharmaceutical Industries in connection with the latter's acquisition
of
Cephalon.
Under terms of the agreement, Par will own the ANDAs for fentanyl
citrate
lozenges, a generic version of Actiq, which is indicated for the
management of
breakthrough cancer pain in patients aged >=16 years with
malignancies who are
already receiving and tolerant to around-the-clock opioid therapy for
their
underlying persistent cancer pain, and cyclobenzaprine
extended-release (ER)
capsules, a generic version of Amrix, indicated as an adjunct to rest
and
physical therapy for the relief of muscle spasm associated with
acute, painful
musculoskeletal conditions, as well as the US rights to market
modafinil
tablets, a generic version of Provigil, a wakefulness-promoting agent.
Par is currently shipping all strengths of fentanyl citrate lozenges
that were
previously available from Teva. Cyclobenzaprine ER capsules and
modafinil
tablets were not previously marketed by Teva, and are not yet
available.
LOAD-DATE: January 6, 2012
LANGUAGE: ENGLISH
PUBLICATION-TYPE: Newsletter
JOURNAL-CODE: Pharma Company Insight
Copyright 2011 Espicom Business Intelligence
All Rights Reserved
15 of 998 DOCUMENTS
PR Newswire
October 18, 2011 Tuesday 9:00 AM EST
Par Pharmaceutical Acquires Three Generic Products From Teva
Pharmaceuticals;
Par Begins Shipping Fentanyl Citrate Lozenges to the Trade Immediately
LENGTH: 453 words
DATELINE: WOODCLIFF LAKE, N.J., Oct. 18, 2011
Par Pharmaceutical Companies, Inc. (NYSE: PRX) announced today that
it acquired
rights to three products from Teva Pharmaceuticals in connection with
Teva's
acquisition of Cephalon. Under terms of the agreement, Par will own
the ANDAs of
fentanyl citrate lozenges, a generic version of Actiq®, and
cyclobenzaprine ER
capsules, the generic version of Amrix®, as well as the U.S. rights
to market
modafinil tablets, the generic version of Provigil®.
According to IMS Health data, annual sales in the U.S. for Actiq®
and the
equivalent generic products are $173 million. Annual sales in the
U.S. for
Provigil® and Amrix® are approximately $1.1 billion and $125
million,
respectively.
Par is currently shipping to the trade all strengths of fentanyl
citrate
lozenges that were previously available from Teva. Cyclobenzaprine ER
capsules
and modafinil tablets were not previously marketed by Teva and are
not yet
available.
About Par Pharmaceutical Companies, Inc.
Par Pharmaceutical Companies, Inc. is a US-based specialty
pharmaceutical
company. Through its wholly-owned subsidiary's two operating
divisions, Par
Pharmaceutical and Strativa Pharmaceuticals, it develops,
manufactures and
markets high barrier-to-entry generic drugs and niche, innovative
proprietary
pharmaceuticals. For press release and other company information,
visit
www.parpharm.com.
Safe Harbor Statement
Certain statements in this news release constitute "forward-looking
statements"
within the meaning of the Private Securities Litigation Reform Act of
1995. To
the extent any statements made in this news release contain
information that is
not historical, these statements are essentially forward-looking and,
as such,
are subject to known and unknown risks, uncertainties and
contingencies, many of
which are beyond the control of the Company, which could cause actual
results
and outcomes to differ materially from those expressed herein. Risk
factors that
might affect such forward-looking statements include those set forth
in Item 1A
of the Company's most recent Annual Report on Form 10-K, in other of
the
Company's filings with the SEC from time to time, including Quarterly
Reports on
Form 10-Q and Current Reports on Form 8-K, and on general industry
and economic
conditions. Any forward-looking statements included in this news
release are
made as of the date hereof only, based on information available to
the Company
as of the date hereof, and, subject to any applicable law to the
contrary, the
Company assumes no obligation to update any forward-looking
statements.
SOURCE Par Pharmaceutical Companies, Inc.
CONTACT:Allison Wey, Vice President, Investor Relations and Corporate
Affairs,
Par Pharmaceutical Companies, Inc., +1-201-802-4000
URL: http://www.prnewswire.com
LOAD-DATE: October 19, 2011
LANGUAGE: ENGLISH
PUBLICATION-TYPE: Newswire
Copyright 2011 PR Newswire Association LLC
All Rights Reserved
16 of 998 DOCUMENTS
Europolitics (daily in English)
October 17, 2011 Monday
MERGERS : ISRAEL'S TEVA CLEARED TO BUY CEPHALON, SUBJECT TO CONDITIONS
BYLINE: Sophie Mosca
SECTION: No. 4286
LENGTH: 246 words
The world's number one generic pharmaceutical company, Teva, obtained
the
European Commission's green light, on 13 October, to buy its American
competitor, Cephalon, which is primarily an originator company. The
EU executive
nevertheless makes the EUR4.5 billion merger contingent on Cephalon's
sale of
its generic version of Provigil, a medicine used to treat excessive
daytime
sleepiness.
The Commission determined that the two groups have a similar generic
drug based
on the same active ingredient as Provigil, namely modafinil, and that
competition on the generic drug markets where modafinil is sold could
be
hampered.
The commitment on the "divestment of Cephalon's generic pipeline
modafinil
product, as offered by the company, will allow a competitor to emerge
and
compete effectively with the merged entity," explains the EU
executive. The
investigation did not reveal any other significant modifications to
the
competitive situation and dynamics of other relevant markets, as a
number of
credible and significant competitors will continue to exercise a
competitive
constraint on the merged entity. The Commission concluded that the
proposed
transaction, as modified by the commitment, would not significantly
impede
effective competition in the European Economic Area.
The US trade regulator, the Federal Trade Commission, made the merger
conditional on Teva's divestment of its Provigil generic, its Actiq
generic used
to treat cancer and Amrix, a muscle relaxant.
LOAD-DATE: October 14, 2011
LANGUAGE: ENGLISH
PUBLICATION-TYPE: Newspaper
JOURNAL-CODE: EURE
Copyright 2011 Europolitique
All Rights Reserved
17 of 998 DOCUMENTS
The Sunday Times (London)
October 16, 2011 Sunday
Edition 1;
National Edition
Doctors given drug perform better surgery;
Tests of the brain-stimulant modafinil on exhausted surgeons produced
remarkable
results, says Jonathan Leake
BYLINE: Jonathan Leake
SECTION: NEWS; Pg. 15
LENGTH: 673 words
IS your doctor on drugs? If not, perhaps they should be. A new study
suggests
that surgeons given "smart drugs" perform better, safer operations.
Researchers gave sleepdeprived surgeons a brain stimulant called
modafinil,
known to boost memory and brain power, and then tested how good they
were at
thinking clearly, solving problems and carrying out simulated
operations.
The results were so convincing that scientists believe the medical
profession
could even be weaned off its current drug of choice: caffeine.
The study, led by Lord Darzi, professor of surgery at Imperial
College London
and a junior health minister in the previous Labour government,
suggests that
doctors whose brains have been sharpened by the drug will perform
better under
pressure.
What is more, he says, their extra brain power means they would think
faster and
react more decisively if something went wrong.
"We found that when surgeons had taken modafinil they saw sharp
improvements in
their ability to solve problems and think flexibly. In fact, their
performance
was very good," said Barbara Sahakian, professor of psychiatry at
Cambridge
University.
The sight of bleary-eyed doctors scrubbing up for surgery after
sleepless nights
in hospital has caused widespread concern over the risk to patients.
But the
usual remedy of strong coffee, taken orally in large quantities, can
cause hand
tremors, the last thing a surgeon needs during a tricky procedure.
Sahakian suggests that modafinil could be a superior substitute for
caffeine.
Sahakian and Charlotte Housden, her research colleague, worked with
Darzi and
his surgical team in conducting the tests.
Housden said: "Sleep deprivation is like being legally drunk - it
causes
problems with learning, memory and increased impulsiveness. This is
particularly
important for people with critical jobs like surgeons, pilots and
drivers.
"Imaging studies show that the pre-frontal cortex, which is where you
do your
thinking, undergoes changes in people who lack sleep."
In the study, Housden and her colleagues tested 39 tired doctors who
had worked
all day and then stayed up all night. They were divided into two
groups: one was
given 200mg of modafinil while the other took a placebo.
Then, from 6am to 8am, the doctors were subjected to a battery of
tests to
measure their cognitive skills, including carrying out virtual
operations using
a surgical training system.
Compared with those who received modafinil, the doctors given a
placebo achieved
much lower scores on memory tasks, were more impatient, less able to
solve
problems and to think flexibly.
Housden said: "Doctors who are deprived of sleep lose their ability
to solve
problems and think flexibly. It means that if they encounter a
surgical problem
they will find it harder to solve.
"However, when they took modafinil they regained their ability to
solve problems
and think flexibly."
Modafinil is currently available only on prescription but it has been
approved
in America for shift workers suffering from sleeping problems while
at work. It
is, however, widely available from online pharmacies for about 50p a
tablet. One
key concern is that modafinil has not been subjected to long-term
safety tests.
Sahakian suggests, however, that, subject to safety approval,
modafinil could
even be offered over the counter.
In other jobs, the use of modafinil has already become widespread -
if hidden.
The military in Britain and America use the drug to keep soldiers and
pilots
awake on long missions and in recent years it has become popular with
students
and, increasingly, with business executives and other groups.
Darzi says in his paper, published in the Annals of Surgery: "The
continuing
discourse over work hours, service provisions, graduate education,
fatigue and
patient safety strongly suggests that novel solutions might
ultimately be
required."
If modafinil can make even the most exhausted of doctors bright-eyed
and
cheerful, then that is a problem solved.
Of course, they could just cut the working hours instead.
Additional reporting: Jan Piotrowski
LOAD-DATE: October 16, 2011
LANGUAGE: ENGLISH
GRAPHIC: Smart drugs might have benefited the medics in Carry on
Doctor
ALLSTAR
PUBLICATION-TYPE: Newspaper
JOURNAL-CODE: STS
Copyright 2011 Times Newspapers Limited
All Rights Reserved
18 of 998 DOCUMENTS
Tendersinfo News
October 15, 2011 Saturday 6:30 AM EST
BELGIUM : Mergers: Commission approves the acquisition of Cephalon by
Teva,
subject to conditions
LENGTH: 338 words
The European Commission has cleared under the EU Merger Regulation
the proposed
acquisition of US-based pharmaceutical company Cephalon by the generic
pharmaceutical company Teva of Israel. The decision is conditional
upon the
divestment of Cephalon's generic version of its "Provigil" drug.
Provigil is
indicated for the treatment of excessive daytime sleepiness
associated with
narcolepsy. Teva has also developed a generic version of the drug. In
light of
the commitments, the Commission concluded that the transaction does
not raise
competition concerns.
The Commission examined the effects of the proposed transaction on
the market
for drugs based on Modafinil, the main active pharmaceutical
ingredient of
Provigil and the generic version developed by Teva as well as the one
Cephalon
has in the pipeline. The Commission was concerned that the proposed
transaction,
as initially notified, would have significantly reduced generic
competition in
the markets where Modafinil is sold.
The Commission's investigation showed that the divestment of
Cephalon's generic
pipeline Modafinil product, as offered by the company, will allow a
competitor
to emerge and compete effectively with the merged entity.
The investigation did not reveal any other significant modification
to the
competitive situation and dynamics of other relevant markets, as a
number of
credible and significant competitors will d continue to exercise a
competitive
constraint on the merged entity.
The Commission therefore concluded that the proposed transaction, as
modified by
the commitment, would not significantly impede effective competition
in the
European Economic Area (EEA)1 or a substantial part of it.
Teva is the world s largest generic pharmaceutical company. Cephalon
is a
primarily originator company, but also supplies generic
pharmaceuticals in the
EEA.
The transaction was notified to the Commission on 25 August 2011.
LOAD-DATE: October 15, 2011
LANGUAGE: ENGLISH
PUBLICATION-TYPE: Web Publication
Copyright 2011 Tendersinfo News, distributed by Contify.com
All Rights Reserved
19 of 998 DOCUMENTS
Globes (Tel Aviv, Israel)
Distributed by McClatchy-Tribune Business News
October 14, 2011 Friday
Teva receives European approval for Cephalon acquisition
BYLINE: Guy Katsovitch, Globes, Tel Aviv, Israel
SECTION: BUSINESS AND FINANCIAL NEWS
LENGTH: 272 words
Oct. 14--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE:
TEVA) and
Cephalon Inc. (Nasdaq: CEPH ) announced today that they received
approval from
the European Commission to proceed with Teva's $7 billion acquisition
of
innovative drugs company Cephalon.
A condition of the approval is that Teva must divest Cephalon's
marketing
authorization of generic modafinil in France and grant to the
purchaser of this
marketing authorization certain additional rights with respect to the
entire
European Economic Area, including a covenant not to sue effective as
of October
2012.
Teva received approval for the US authorities for the merger at the
beginning of
the week. Under that approval, Teva is required to divest two ANDAs
for fentanyl
citrate lozenges, a generic version of Actiq, and cyclobenzaprine ER
capsules,
the generic version of Amrix. Teva will also grant non-exclusive U.S.
rights to
an undisclosed company to market modafinil tablets, the generic
version of
Provigil, which had annual brand sales in the US of approximately
$1.1 billion.
With the European Commission approval, the parties have now obtained
all
regulatory approvals required to close the transaction and,
accordingly, have
scheduled a closing date of October 14, 2011.
Teva projects that the deal will be accretive on a non-GAAP basis as
soon as it
is completed, and on a GAAP basis within four quarters. Teva also
expects
synergies of $500 million in the third year after completion.
___ (c)2011 the Globes (Tel Aviv, Israel) Visit the Globes (Tel Aviv,
Israel) at
www.globes.co.il/serveen/globes/nodeview.asp?fid=942 Distributed by
MCT
Information Services
LOAD-DATE: October 15, 2011
LANGUAGE: ENGLISH
ACC-NO:
20111014-TL-Teva-receives-European-approval-for-Cephalon-acquisition-1
014-201110
14
PUBLICATION-TYPE: Newspaper
JOURNAL-CODE: TL
Copyright 2011 Globes (Tel Aviv, Israel)
20 of 998 DOCUMENTS
States News Service
October 14, 2011 Friday
MERGERS: COMMISSION APPROVES THE ACQUISITION OF CEPHALON BY TEVA,
SUBJECT TO
CONDITIONS
BYLINE: States News Service
LENGTH: 459 words
DATELINE: BRUSSELS
The following information was released by the European Union:
The European Commission has cleared under the EU Merger Regulation
the proposed
acquisition of US-based pharmaceutical company Cephalon by the generic
pharmaceutical company Teva of Israel. The decision is conditional
upon the
divestment of Cephalon's generic version of its "Provigil" drug.
Provigil is
indicated for the treatment of excessive daytime sleepiness
associated with
narcolepsy. Teva has also developed a generic version of the drug. In
light of
the commitments, the Commission concluded that the transaction does
not raise
competition concerns.
The Commission examined the effects of the proposed transaction on
the market
for drugs based on Modafinil, the main active pharmaceutical
ingredient of
Provigil and the generic version developed by Teva as well as the one
Cephalon
has in the pipeline. The Commission was concerned that the proposed
transaction,
as initially notified, would have significantly reduced generic
competition in
the markets where Modafinil is sold.
The Commission's investigation showed that the divestment of
Cephalon's generic
pipeline Modafinil product, as offered by the company, will allow a
competitor
to emerge and compete effectively with the merged entity.
The investigation did not reveal any other significant modification
to the
competitive situation and dynamics of other relevant markets, as a
number of
credible and significant competitors will d continue to exercise a
competitive
constraint on the merged entity.
The Commission therefore concluded that the proposed transaction, as
modified by
the commitment, would not significantly impede effective competition
in the
European Economic Area (EEA)1 or a substantial part of it.
Teva is the world's largest generic pharmaceutical company. Cephalon
is a
primarily originator company, but also supplies generic
pharmaceuticals in the
EEA.
The transaction was notified to the Commission on 25 August 2011.
Merger control rules and procedures
The Commission, in 1989, was given the power to assess mergers and
acquisitions
involving companies with a turnover above certain thresholds (see
Article 1 of
the Merger Regulation). Its duty is to prevent concentrations that
would
significantly impede effective competition in the EEA or any
substantial part of
it.
The vast majority of mergers do not pose competition problems and are
cleared
after a routine review. From the moment a transaction is notified, the
Commission generally has a total of 25 working days to decide whether
to grant
approval (Phase I) or to start an in-depth investigation (Phase II).
A non-confidential version of today's decision will be available at:
http://ec.europa.eu/competition/elojade/isef/case_details.cfm?proc_cod
e=2_M_6258
LOAD-DATE: October 14, 2011
LANGUAGE: ENGLISH
PUBLICATION-TYPE: Newswire
Copyright 2011 States News Service
21 of 998 DOCUMENTS
States News Service
October 14, 2011 Friday
PRELIMINARY STUDY EXAMINES EFFECTS OF 'COGNITIVE ENHANCEMENT' DRUG ON
SLEEP-DEPRIVED DOCTORS
BYLINE: States News Service
LENGTH: 919 words
DATELINE: LONDON
The following information was released by Imperial College London:
Researchers have carried out a preliminary study looking at the
effects of the
'cognitive enhancement' drug modafinil on the performance of doctors
who had
been deprived of sleep for one night.
Modafinil, discovered in the 1970s, is currently prescribed in the UK
for the
treatment of sleepiness associated with narcolepsy, sleep apnoea, and
shift work
sleep disorder, a condition that affects people who frequently have
to work at
night.
In the new study of 39 people, published today in the Annals of
Surgery by
researchers from Imperial College London and the University of
Cambridge,
modafinil improved performance in a series of mental tasks when
compared with
placebo, but had no effect on the performance of a surgical motor
skills task.
The doctors did not interact with any patients during the exercise.
See also:
Annals of Surgery
Imperial College London is not responsible for the content of
external internet
sites
Department of Surgery and Cancer
Faculty of Medicine
Long periods without sleep are known to increase doctors' risk of
making poor
judgements and committing medical errors. The study was designed as a
preliminary investigation into whether certain drugs might be
effective at
reversing some of the effects of fatigue.
Colin Sugden, Clinical Lecturer in Surgery, Department of Surgery and
Cancer at
Imperial College London, who led the study, said: "This study set out
to explore
whether modafinil, a wakefulness-promoting drug, might help doctors
to perform
more effectively under conditions of fatigue when their performance
might
otherwise be compromised."
In this randomised double-blind trial, 20 healthy male doctors took
modafinil
and 19 took a placebo after one night of sleep deprivation. All were
asked to
complete both a series of tasks that are commonly used in psychology
research
and a virtual reality surgical motor skills task.
In the psychological tasks, the group that had taken modafinil
performed better
in tests of working memory and planning, were less impulsive
decision-makers,
and were more responsive to changing demands during a task. However,
there was
no significant difference between the two groups on the surgical
motor skills
task.
Mr Sugden said: "Participants in the modafinil group were less
impulsive,
displayed greater flexibility and solved working memory and planning
problems
more efficiently than those in the placebo group. However, no benefit
was seen
in the performance of a basic motor skills task. This was a small,
short-term
study so we have to be very cautious about how the results are
interpreted. Most
importantly, it is not clear how performance on tests of mental
function relate
to how someone performs as a doctor."
The researchers stress that these results remain to be confirmed with
a larger
sample size and ideally in a longer term study.
The research explored the effects of one dose of modafinil over a
short term and
it was not designed to investigate the effects of repeated use,
either on a
person's physical and mental health or on their performance.
Mr Sugden said: "Larger studies looking at the performance effects
and safety of
longer term use of the drug would need to be performed before we
could draw
conclusions about whether or not sleep-deprived doctors might benefit
from
taking it. There are also many challenging ethical considerations
which will
need to be thought through very carefully.
"We should continue to do everything we can to ensure that doctors
aren't in a
situation where fatigue might impact upon their performance. We don't
suggest
that anyone should take modafinil to combat sleep deprivation, unless
it has
been prescribed by a doctor.
The study was funded by Imperial College London.
-ENDS-
For further information please contact:
Simon Levey
Research Media Officer
Imperial College London
e-mail: s.levey@imperial.ac.uk
Telephone: +44 (0)207 594 6702 or ext. 46702
Out of hours duty Press Officer: +44 (0)7803 886 248
Notes to editors:
1. Journal reference: C. Sugden et al. Effect of pharmacological
enhancement on
the cognitive and clinical psychomotor performance of sleep deprived
doctors.
Annals of Surgery, 2011 DOI: 10.1097/SLA.0b013e3182306c99
2. About Imperial College London
Consistently rated amongst the world's best universities, Imperial
College
London is a science-based institution with a reputation for
excellence in
teaching and research that attracts 14,000 students and 6,000 staff
of the
highest international quality. Innovative research at the College
explores the
interface between science, medicine, engineering and business,
delivering
practical solutions that improve quality of life and the environment -
underpinned by a dynamic enterprise culture.
Since its foundation in 1907, Imperial's contributions to society
have included
the discovery of penicillin, the development of holography and the
foundations
of fibre optics. This commitment to the application of research for
the benefit
of all continues today, with current focuses including
interdisciplinary
collaborations to improve global health, tackle climate change,
develop
sustainable sources of energy and address security challenges.
In 2007, Imperial College London and Imperial College Healthcare NHS
Trust
formed the UK's first Academic Health Science Centre. This unique
partnership…[File truncated due to length; see original file]…